Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma


Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Untreated Childhood Rhabdomyosarcoma

What is the purpose of this trial?

This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.

Participation Guidelines

N/A - 49 Years

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
January 2010
Last Updated:
February 10, 2015
Study HIC#:

Clinicaltrials.gov ID: NCT01055314